Olfactory disturbances caused by the anti-cancer drug tegafur.
Olfactory disturbances induced by the anti-cancer drug tegafur were studied in separate clinical and experimental investigations. Five patients with olfactory dysfunction after tegafur were studied and were found to have normal endoscopic findings of the olfactory cleft mucosa. The average period for drug administration was 22 months. Recovery from the olfactory disturbance was poor and biopsy of the olfactory mucosa revealed severely degenerated epithelium. In experimental studies in a guinea pig animal model, effects of oral tegafur on mitotic cells in the olfactory epithelium were examined using bromodeoxyuridine (BrdU) uptake as index. At the conclusion of 3 weeks' treatment, no pronounced morphological changes were seen, but the number of BrdU-incorporating cells decreased in proportion to the dose of tegafur used. Following long-term administration of tegafur 18 months, mitotic cells reacting to BrdU or proliferating cell nuclear antigen had virtually disappeared, indicating persistent inhibition of mitotic cell activity. Morphological changes present included decreased olfactory cell numbers, loss of cells in areas just above basal cells and degeneration of the mucous layer.
Nakamura
H
H
Department of Otorhinolaryngology, Niigata University School of Medicine, Japan.
Nonomura
N
N
Fujiwara
M
M
Nakano
Y
Y
D000328:Adult; D000818:Animals; D001973:Bromodeoxyuridine; D002452:Cell Count / Q000187:drug effects; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D008679:Metaplasia; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects; D000857:Olfaction Disorders / Q000139:chemically induced*; D009831:Olfactory Mucosa / Q000187:drug effects / Q000473:pathology; D018034:Olfactory Receptor Neurons / Q000187:drug effects / Q000473:pathology; D018809:Proliferating Cell Nuclear Antigen; D012903:Smell / Q000187:drug effects*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D018809:Proliferating Cell Nuclear Antigen; D005641:Tegafur; D001973:Bromodeoxyuridine